The trouble with fat-burner pills.
Smith
I K
IK
D018663:Adrenergic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000329:Advertising; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000191:economics; D003257:Consumer Product Safety; D004041:Dietary Fats; D019587:Dietary Supplements / Q000009:adverse effects* / Q000191:economics; D004809:Ephedrine / Q000009:adverse effects / Q000627:therapeutic use; D015444:Exercise; D006801:Humans; D012307:Risk Factors; D014481:United States; D015431:Weight Loss
D018663:Adrenergic Agents; D019440:Anti-Obesity Agents; D004041:Dietary Fats; D004809:Ephedrine